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Living Donor Kidney Transplantation Should Be 
Promoted Among “Elderly” Patients
Mirjam Laging, PhD,1 Judith A. Kal-van Gestel, MSc,1 Willem Weimar, MD, PhD,1 and  
Joke I. Roodnat, MD, PhD1
Over the years, elderly patients were increasingly referred for renal transplantation and this eventually led to lib-
eralization of age criteria for transplantation,1-3 resulting in an 
increase in the representation of elderly patients on the wait-
ing list (Figure 1). In most studies, elderly was defined as ≥65 
years. Although patient survival is better in the elderly popu-
lation that received a kidney transplantation, compared with 
dialysis,2-4 age is still an important factor for nonreferral for 
kidney transplantation.5,6 In Rotterdam, no age limit is used. 
All patients are screened based on total health and social sup-
port status. However, because elderly more often suffer from 
comorbidities7 the chance to be declined is higher compared 
with younger candidates.
In some countries, living donor kidney transplantation 
(LDKT) is performed on a large scale. In the Netherlands, 
LDKT even outnumbers deceased donor kidney transplanta-
tion (DDKT).8 Patients are preferentially transplanted with a 
living donor kidney, because the outcomes of LDKT are supe-
rior compared with those of DDKT.9 Additionally, LDKT can 
be performed without the delay of waiting time. Patients with-
out a living donor are placed on the waiting list for a deceased 
donor transplant. In our center, a liberal policy regarding 
acceptance of donation after circulatory death and dona-
tion after brain death is applied. Our center also participates 
in the Eurotransplant Senior Program10 and the Acceptable 
Kidney Transplantation
Background. Age criteria for kidney transplantation have been liberalized over the years resulting in more waitlisted 
elderly patients. What are the prospects of elderly patients on the waiting list? Methods. Between 2000 and 2013, 2622 
patients had been waitlisted. Waiting time was defined as the period between dialysis onset and being delisted. Patients 
were categorized according to age upon listing: <25; 25–44; 45–54; 55–64; and >64 years. Furthermore, the influence 
of ABO blood type and panel reactive antibodies on outflow patterns was studied. Results. At the end of observation 
(November 2017), 1957 (75%) patients had been transplanted, 333 (13%) had been delisted without a transplantation, 271 
(10%) had died, and 61 (2%) were still waiting. When comparing the age categories, outflow patterns were completely dif-
ferent. The percentage of patients transplanted decreased with increasing age, while the percentage of patients that had 
been delisted or had died increased with increasing age, especially in the population without living donor. Within 6 years, 
93% of the population <25 years had received a (primarily living) donor kidney. In the populations >55 years, 39% received a 
living donor kidney, while >50% of patients without a living donor had been delisted/died. Multivariable analysis showed that 
the influence of age, ABO blood type, and panel reactive antibodies on outflow patterns was significant, but the magnitude 
of the influence of the latter 2 was only modest compared with that of age. Conclusions. “Elderly” (not only >64 y but 
even 55–64 y) received a living donor kidney transplantation less often. Moreover, they cannot bear the waiting time for a 
deceased donor kidney, resulting in delisting without a transplant in more than half the population of patients without a living 
donor. Promoting living donor kidney transplantation is the only modification that improves transplantation and decreases 
delisting/death on the waiting list in this population.
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Mismatch Program.11 In the Netherlands, the availability of 
deceased donor organs has been stable throughout the years. 
In the Eurotransplant area, waiting time starts when dialysis 
is started. Unfortunately, waiting time may be up to several 
years, while both age and waiting time are important risk fac-
tors for death on the waiting list.12,13
What is the chance of receiving a kidney transplant while 
on the waiting list and what is the influence of age on this 
chance? Blood type and panel reactive antibodies (PRA) are 
known to influence outflow from the waiting list.14-18 In order 
to put the influence of age in perspective, we also included 
these variables and their interactions into the analysis.
MATERIALS AND METHODS
Study Sample
Between January 1, 2000 and December 31, 2013, 2663 
patients had been placed on the regional waiting list for kid-
ney transplantation. Forty-one patients were removed from 
the waiting list; 6 due to wrong listing and 35 since their renal 
function had recovered. Consequently, 2622 patients were 
included in this retrospective cohort study (Figure 2). Waiting 
time was defined as time between first dialysis date and being 
removed from the waiting list. For enlisted transplant patients 
whose transplant failed within 90 days, waiting time for the 
previous transplant was added to current waiting time.
The waiting list was retrieved from Eurotransplant. For 
patients for whom no dialysis onset date was present in the 
Eurotransplant database, patient records of our hospital sys-
tem were checked. This resulted in 147 corrections. In 56 
cases (2.1%), information on dialysis could not be retrieved 
from the patient records. In these cases, Eurotransplant data 
were used which means that for these patients waiting time 
was zero as we presumed that dialysis had not been initiated.
Variables
Available variables were age, ABO blood type, maximum 
PRA, and patient gender. Nine hundred eighty-seven patients 
were females and 1635 males. Patients were categorized into 
5 categories according to age at inflow on the waiting list 
(Table  1). In the oldest age category, 58 patients were >74 
years and 7 patients were between 80 and 84 years. The mean 
age in the oldest category was 69.6, the median age 69, and 
the SD 3.6 years. Patients were categorized into 4 catego-
ries according to maximum PRA at inflow on the waiting 
list (Table  1). ABO blood type of all patients was included 
(Table 1).
Reasons for outflow from the waiting list were: (1) died or 
delisted, (2) still waiting, (3) DDKT, and (4) LDKT. Patients 
transplanted abroad all received a living donor kidney and 
thus were included in LDKT. Observation was until November 
1, 2017.
Patient Data and Ethics
The data for this study were retrospectively retrieved from 
patient files and Eurotransplant registry data. All patient data 
were anonymized. According to the Dutch law on medical 
research on human subjects, it was not deemed necessary to 
obtain written informed consent from the patients for this 
study.
Patients whose data were retrieved for this study were 
treated in accordance with the Declaration of Helsinki and 
the Declaration of Istanbul.
Statistical Analyses
Outflow patterns were created by scoring outflow reasons 
before dialysis (time point 0) and at 1, 2, 3, 4, 5, and 6 years 
after dialysis onset for each patient. For instance, when a 
patient had been on dialysis for 2.5 years before receiving a 
Year
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FIGURE 1. Age distribution of patients on the waiting list for kidney transplantation in the study period per y.
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LDKT, time points 0, 1, and 2 were scored as still on the wait-
ing list and time points 3, 4, 5, and 6 as LDKT. Patients with 
an observed waiting time shorter than 6 years were censored. 
Chi-square tests were performed to test the difference in out-
flow reasons between the age categories, ABO blood types, 
and PRA categories. Age, ABO blood type, maximum PRA, 
and gender were included in multivariable Cox proportional 
hazard analysis to assess the likelihood of either a living or 
deceased donor transplantation. Age was included as continu-
ous variable. Cases with missing values were excluded. SPSS 
version 25 (IBM Corporation, Armonk, NY) was used to per-
form all statistical analyses. P values <0.05 were considered 
significant.
RESULTS
Out of the 2622 waitlisted patients, 1957 (75%) had 
been transplanted before November 2017: 674 patients had 
received a DDKT, 1273 an LDKT, and 10 had been trans-
planted abroad (Figure 2). Out of the 665 (25%) patients who 
FIGURE 2. Flowchart of outflow of patients enlisted between January 2000 and December 2013. End of observation was November 1, 2017.
TABLE 1.
Percentages of ABO blood type, PRA, and gender per age category
Age category
Overall P <25 (N = 122) 25–44 (N = 600) 45–54 (N = 584) 55–64 (N = 752) >64 (N = 564)
ABO A N = 1046 38.5 40.3 38.4 43.8 36.2 0.002
 AB N = 125 3.3 4.3 5.5 4.0 5.9  
 B N = 361 18.9 14.5 18.0
b
10.9
a
11.3
a
 
 O N = 1090 39.3 40.8 38.2
b
41.4 46.6
a
 
PRA 0 N = 1391 56.2 46.0
b
51.9 55.3
a
59.6
a
<0.001
 1–4 N = 638 17.4 25.3 22.7 26.4 24.5  
 5–85 N = 508 19.8 23.7
c
23.0
b,c
17.2
a,b
14.4
a
 
 86–100 N = 69 6.6
a
5.1
a
2.4 1.1
b
1.6
b
 
Gender F N = 987 45.1 42.2
b
38.0 36.6 32.3
a
0.004
 M N = 1635 54.9 57.8
b
62.0 63.4 67.7
a
 
Different subscript letters in the same row mean a significant difference at the 0.05 level.
PRA, panel reactive antibodies.
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had not been transplanted, 333 had been delisted without a 
kidney transplantation and 271 had died while on the wait-
ing list. The remaining 61 (2%) patients were still waiting in 
November 2017.
Most important reasons for delisting were a deteriorated 
condition (76%) and patient withdrawal (12%). For the 
different age categories “unfitness for transplantation” was 
responsible for delisting in 0% in the youngest; 58% in 25–44 
years; 65% in 45–54 years; 82% in 55–64 years; and 81% in 
the oldest age group.
Outflow per Year
In Figure 3, the reasons for outflow per year for the total 
population and per age category are shown. The x-axis shows 
waiting time in years after dialysis onset, the y-axis shows the 
percentage of patients. Light gray represents the percentage 
of patients who had received an LDKT and medium gray the 
patients who had received a DDKT. The shaded area repre-
sents censored patients. Their period on dialysis and/or their 
observation time was <6 years. White represents the patients 
who were still on the waiting list. Finally, dark gray repre-
sents the patients who had died or had been delisted without 
a transplant.
Time Point 0
Figure 3 shows that in none of the age categories the per-
centage of patients waiting at time point 0 was 100%. This 
means that some patients were removed from the list because 
of preemptive transplantation or because of death or delisting 
before dialysis onset. The percentage of preemptive transplan-
tation decreased with increasing age category (P  =  0.005), 
while the percentage of patients who had died or had been 
delisted before dialysis onset increased with increasing age 
(P < 0.001). Patients who were not on dialysis at the end of 
FIGURE 3. Percentage of patients who had died or been delisted (dark gray), still waiting (white), censored (shaded), or underwent 
deceased donor (DD; medium gray) or living donor (LD; light gray) kidney transplantation per y for the total population and each age 
category. Patients who were not waiting on time point 0 had been preemptively transplanted, been censored, died, or been delisted before 
dialysis onset.
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observation (November 1, 2017) were censored (shaded area 
in Figure 3).
Time Point 6
After 6 years observation, 93% of patients in the young-
est category had been transplanted, the vast majority with an 
LDKT (Figure 3; light gray). Both the percentage of patients 
transplanted within 6 years and the proportion of LDKT 
decreased with increasing age (P < 0.001, P < 0.05). In age 
category 25–44 years, 82% had been transplanted; in cate-
gory 45–54, 77%; in category 55–64, 68%; and in category 
>64 only 58% had been transplanted. Slightly more than half 
of transplanted patients >64 years received an LDKT. In con-
trast, the percentage of patients who had died or had been 
delisted without a transplant increased with increasing age (P 
< 0.001). Within 6 years, respectively, 3%; 9%; 15%; 27%; 
and 39% of patients in the consecutive age categories had 
died or had been delisted.
Patients Without Living Donor
When patients with an LDKT and censored patients are 
excluded from the observation (excluding the light gray and 
shaded areas in Figure 3), the contribution of DDKT decreased 
with increasing age. The contribution of delisting/death 
increased from 14%, in the youngest, to 52% in age category 
55–64 years and even 57% in the population >64 years.
The Influence of Time on Outflow Patterns
As illustrated in Figure 3, the differences between the age 
categories occurred within the first few years. In all age catego-
ries, most LDKTs had been performed preemptively or within 
2 years after dialysis onset. However, this accounted for the 
majority (70%) of youngest patients but only for a minority 
(27%) of oldest patients. From 2 years onwards, LDKT lev-
eled off. The proportion of DDKT gradually increased over 
time from T0 onwards. In the first few years, the proportion 
of patients who had died or had been delisted without a trans-
plant increased with age. After 2 years, 25% of patients in 
the oldest age category had died or had been delisted. The 
percentage leveled off after 4 years. Over the course of the 
6 years, in the oldest age category, the cumulative number 
of patients who had died or had been delisted was signifi-
cantly higher compared with the number of patients who had 
received a DDKT as is shown in Figure 3 (P < 0.05). Reasons 
for outflow differed significantly between the age categories 
(P < 0.001) at all time points (0–6 y).
ABO Blood Type
In Figure  4, the reasons for outflow per year per ABO 
blood type are shown. The mean age was 52.3 years in 
patients with blood type A (N = 1046); 53.5 in blood type AB 
(N = 125); 50.6 in blood type B (N = 361); and 53.1 in blood 
type O (N = 1090) (P = 0.002). Reasons for outflow signifi-
cantly differed between the ABO blood types (P < 0.001) at 
all time points (0–6 y). From 4 years onwards, significantly 
more patients with blood type O had died/been delisted 
compared with blood type A (P < 0.05). After 6 years, 19% 
(A); 18% (AB); 20% (B); and 25% (O) of patients had died 
or had been delisted. Patients with blood type O (from 2 y 
onwards) and blood type B (from 1 y onwards) had received 
an LDKT significantly less often than patients with blood 
type A (P < 0.05). At all time points, patients with blood type 
AB had received a DDKT more often than the other catego-
ries (P < 0.05). At all time points, significantly fewer patients 
FIGURE 4. Percentage of patients who had died or been delisted (dark gray), still waiting (white), censored (shaded), or underwent deceased 
donor (DD; medium gray) or living donor (LD; light gray) kidney transplantation per y per ABO blood type. Patients who were not waiting on time 
point 0 had been preemptively transplanted, been censored, died, or been delisted before dialysis onset.
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with blood type O and, until year 4, blood type B had been 
transplanted with either an LDKT or DDKT compared with 
patients with blood types A and AB (P < 0.05). After 6 years, 
77% of patients with blood type A; 81% with blood type 
AB; 71% with blood type B; and 68% with blood type O 
had been transplanted.
Panel Reactive Antibodies
In Figure 5, the reasons for outflow per year per PRA cat-
egory are shown. PRA was missing in 16 cases (0.6%). The 
mean age was 53.5 years in patients with PRA 0 (N = 1391); 
52.9 in PRA 1–4 (N = 638); 50.4 in PRA 5–85 (N = 508); 
and 43.8 in PRA 86–100 (N = 69) (P < 0.001). The percent-
age of patients who had received an LDKT was lower in the 
highest PRA category (86–100) compared with unsensitized 
patients (PRA 0 and PRA 1–4) (P < 0.05). From 2 years 
onwards, the difference in LDKT between PRA 86–100 and 
PRA 5–85 was significant as well (P < 0.05). In contrast, 
more patients in the highest PRA category (86–100) had 
received a DDKT compared with all other categories from 
1 year onwards (P < 0.05). At all time points except year 
1, significantly more patients with PRA 0 had been trans-
planted with either an LDKT or DDKT compared with 
patients with PRA 5–85 (P < 0.05). The differences between 
all other categories were not significant. After 6 years, in 
PRA category 0, 75%; in category 1–4, 72%; in category 
5–85, 67%; and in category 86–100, 65% had been trans-
planted. The differences in patients who had died or had 
been delisted without a transplant were not significant. 
After 6 years, respectively, 21%; 22%; 25%; and 19% of 
patients in the consecutive PRA categories had died or had 
been delisted.
Adjusted Analysis
Table 1 shows percentages of ABO blood type, PRA, and 
gender per age category. The difference in age distribution was 
significant for all other covariates. The overall P values were 
0.002; <0.001; and 0.004, respectively. Patients in the oldest 
age group more often had blood type O, but PRA was lower 
in the oldest patients.
In multivariable Cox proportional hazard analysis age, 
ABO blood type, PRA, and gender had a significant influ-
ence on the likelihood of transplantation (P < 0.001; <0.001; 
<0.001; 0.007, respectively). The likelihood of transplan-
tation decreased per year with increasing age (relative risk 
[RR] = 0.987). Compared with ABO blood type A, the likeli-
hood of blood type AB was higher (RR = 1.260; P = 0.029), 
and of blood types B and O lower (RR = 0.733; P < 0.001 
and RR = 0.705; P < 0.001 respectively). Compared with PRA 
0%, the likelihood of PRA 5%–85% and PRA 86%–100% 
was lower (RR = 0.731; P < 0.001 and RR = 0.535; P < 0.001, 
respectively). The difference between PRA 0% and PRA 1%–
4% was not significant. The likelihood of transplantation was 
lower for female patients than for male patients (RR = 0.879; 
P = 0.007). There was no significant interaction between age 
and the other covariates and between ABO blood type and 
PRA (P > 0.500 for all interactions).
As an example, in Figure  6, the combined influence of 
patient age, ABO blood types A and O, and PRA 0% and 
86%–100% on the likelihood of receiving either a living or 
deceased donor transplant is shown, based on the multivari-
able Cox proportional hazard model described above. The 
reference value is the likelihood of a 20-year-old patient 
with blood type A and PRA 0% (RR = 1). The likelihood of 
transplantation decreased considerably with increasing age. 
FIGURE 5. Percentage of patients who had died or been delisted (dark gray), still waiting (white), censored (shaded), or underwent deceased 
donor (DD; medium gray) or living donor (LD; light gray) kidney transplantation per y per PRA category. Patients who were not waiting on time 
point 0 had been preemptively transplanted, been censored, died, or been delisted before dialysis onset. PRA, panel reactive antibodies.
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Furthermore, Figure 6 shows that the likelihood of transplan-
tation was highest for young, unsensitized patients with blood 
type A, but also that highly sensitized blood type A patients 
had a slightly lower likelihood than unsensitized blood type 
O patients. The results of blood type B patients were compa-
rable to those of blood type O patients (data not shown). As 
expected, the likelihood for patients with blood type AB was 
highest (data not shown).
DISCUSSION
For patients who are being placed on the waiting list for 
DDKT, the most relevant question is how long they will 
have to wait for a kidney offer. To answer that question, the 
median waiting time can be given. However, that does not 
take into account other reasons for delisting; LDKT, death, 
or a deterioration in condition. Thus, an additional ques-
tion that should be answered is whether or not they will 
survive the waiting time and stay in adequate condition 
until transplantation. To date, only a few papers have been 
published in which all reasons for outflow from the waiting 
list were taken into account.15-18 Factors that were found 
to significantly influence the chance of becoming trans-
planted were the well-known variables age, ABO blood 
type, PRA, and HLA frequency.15-17 In 2009, Schold et al18 
found that nearly half of elderly (>60 y) waitlisted patients 
were estimated to die before DDKT. However, results were 
not compared with those of younger patients as they were 
not included in the study. Moreover, in the Kaplan-Meier 
analysis that was used, transplantation and delisting (due 
to decreased physical condition) were not accounted for. In 
our current analysis, the results represent the actual situa-
tion in the population.
Figure  3 shows that outflow patterns are time depend-
ent and that there are differences between outflow patterns 
for categories of patients. Outflow from the waiting list is a 
dynamic process whereby outflow patterns vary with both age 
and time after listing. The effect of time on outflow reasons is 
clearly visible: LDKT was primarily performed in the first 2 
years after start dialysis, whereas DDKT gradually increased 
after dialysis onset. Most cases of death or delisting occurred 
in the first 2 years after start dialysis and the increase dimin-
ished after that time.
In the current study, large differences in outflow from the 
waiting list between the age categories were found. In the 2 
highest age categories, 27% (55–64 y) and 39% (>64 y) of 
patients accepted for transplantation were not transplanted 
because they had died or their condition had deteriorated 
within 6 years on dialysis. For patients who did not have a 
living donor, percentages were even higher. More than half 
the patients aged >54 years without a living donor had not 
been transplanted (Figure 3). As was shown, the number of 
elderly patients who had died or had been delisted increased 
profoundly in the first years after start dialysis. As the mean 
waiting time for DDKT is 3–4 years, they did not survive the 
wait for a deceased donor kidney in adequate condition.
In a previous study, we found that patients with ABO blood 
type O and patients with a PRA >85 have a significantly longer 
waiting time.14 In the present study, we confirmed that blood 
types O and, to a lesser extent, B waited longer. Percentages 
of patients with LDKT and DDKT were significantly dif-
ferent between blood types as shown in Figure 4. However, 
the difference in percentage of patients who had died or had 
been delisted between ABO blood types O and A was only 
significant from 4 years onwards. Although the influence of 
ABO blood type on the percentage of patients who had died 
or had been delisted was significant, the difference between 
ABO blood types was only modest (range 18%–25%). On the 
other hand, the influence of age on the percentage of patients 
who had died or had been delisted was also significant, but 
the magnitude of the difference between the age categories is 
noteworthy (range 3%–39%).
The longer waiting time of highly sensitized patients was 
confirmed as well. Because of the Acceptable Mismatch 
Program, these patients received a DDKT more often.11 
However, the percentage of LDKT was very low. The differ-
ence in percentage of patients who had died or been delisted 
between PRA categories was not significant.
As was shown in multivariable analysis age, ABO blood 
type, and PRA all had an independent influence on the likeli-
hood of transplantation. Figures 3, 4, and 5 clearly show the 
paramount importance of age on outflow from the waiting 
list. ABO blood type and PRA were less influential when com-
paring both the percentages of patients who had died or had 
been delisted and the percentages of patients who had been 
transplanted after 6 years. In multivariable analysis, there was 
FIGURE 6. The combined influence of patient age, ABO blood types A (solid lines) and O (dashed lines), and PRA 0% (dark lines) and 86%–
100% (light lines) on the likelihood (RR) of receiving either a living or deceased donor transplant. The reference value is the likelihood of a 20-y-old 
patient with blood type A and PRA 0% (RR = 1). Between ages 20 and 60 y, the RR decreased by 40%. The RR of patients with blood type O 
was 26% lower than blood type A. The RR of patients with PRA 86%–100% was 37% lower than PRA 0%. PRA, panel reactive antibodies; RR, 
relative risk.
8 Transplantation DIRECT   ■   2019 www.transplantationdirect.com
no interaction between the variables studied, but of course 
the likelihood of transplantation decreases in the presence of 
multiple unfavorable variables.
In the elderly population, fewer patients are transplanted 
with a living donor kidney. Also, when observing the popula-
tion that already received a kidney transplantation, there is 
a preponderance of DDKT in the elderly.19-21 In the elderly 
population with renal disease, comorbidity is more prevalent.7 
A longer period on dialysis may further decrease the physi-
cal condition, precluding transplantation. As survival among 
transplanted patients with comorbidity generally is better 
compared with patients who remain on dialysis,7,22 transplan-
tation should not be delayed but should be performed when 
their condition is at best. Promoting LDKT is the only modifi-
able factor that may increase the number of transplantations 
performed in elderly patients with or without comorbidity.
A reduction of racial disparity in access to LDKT has 
been attained by including patients’ social networks in edu-
cation on renal replacement therapies using house call inter-
ventions.23,24 Such interventions may be useful in the elderly 
population as well. They could try to find peers, relatives, or 
other persons from their social network to donate to them. 
This is challenging due to increasing age and the likelihood of 
contraindications in their peers.
In Eurotransplant, deceased donor allocation, apart from 
Eurotransplant Senior Program and pediatric status, age is 
not a selection criterion for matching. The allocation policy 
of Eurotransplant is comparable to policies in for instance the 
United States, United Kingdom, Scandinavia, and Australia 
and New Zealand.25-29 Generally, the most important match-
ing criteria in all allocation systems are ABO blood type, 
HLA-matching, waiting time, and distance from donor hos-
pital. PRA is an allocation criterion in Eurotransplant, the 
United Kingdom, Scandinavia, and Australia but not in the 
United States and New Zealand.
A possible limitation of single-center studies in general 
may be the generalizability. In our center, there is a relatively 
large population of LDKT recipients. In the population that 
received an LDKT, younger patients and patients without 
comorbidity are overrepresented.7 However, a relatively large 
percentage of the elderly received an LDKT. Although patient 
selection for medical reasons cannot be completely ruled out, 
DDKT allocation is independent of the presence of an LDKT 
program. After exclusion of the LDKT population, it is obvi-
ous that the elderly population that is dependent on DDKT 
lags behind and half of them are removed from the waiting list 
without a transplant. In centers without an LDKT program, 
percentages of elderly patients delisted without a transplant 
may even be higher.
Another limitation is that no information on active listing 
was available. The proportion of (temporarily) not trans-
plantable elderly patients could be higher than the proportion 
of (temporarily) not transplantable younger patients. This 
may have led to longer waiting times, less transplants, and 
more delisting/deaths in the older age categories. In the future, 
active listing status should be registered so that in follow-up 
studies this information can be taken into account to verify 
the outflow patterns.
In conclusion, our study on the influence of age, ABO 
blood type, and PRA on the outcome of patients on the wait-
ing list showed that age far overrides the influence of both 
other factors.
The percentage of patients who had been delisted or had 
died without a transplant increased strikingly with age. When 
no living donor was available, 54% of patients >54 years had 
died or been delisted after 6 years. As LDKT is the only modi-
fiable factor to promote transplantation without delay in this 
population, our results stress the importance of finding a liv-
ing donor for these “elderly” patients.
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